Head-To-Head Review: Global Industrial (NYSE:GIC) & Capstone Therapeutics (NASDAQ:CAPS)

Global Industrial (NYSE:GIC) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Volatility and Risk

Global Industrial has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.

Insider & Institutional Ownership

31.2% of Global Industrial shares are held by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are held by institutional investors. 64.5% of Global Industrial shares are held by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Global Industrial and Capstone Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Industrial	$1.38 billion	1.21	$72.10 million	$2.24	19.56
Capstone Therapeutics	$48.11 million	1.16	-$21.23 million	($3.35)	-0.81

Global Industrial has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Global Industrial, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Global Industrial and Capstone Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Industrial	0	3	0	0	2.00
Capstone Therapeutics	1	0	0	0	1.00

Global Industrial currently has a consensus target price of $39.00, indicating a potential downside of 11.01%. Given Global Industrial’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Global Industrial is more favorable than Capstone Therapeutics.

Profitability

This table compares Global Industrial and Capstone Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Industrial	6.06%	21.49%	11.60%
Capstone Therapeutics	-36.51%	-144.43%	-40.48%

Summary

Global Industrial beats Capstone Therapeutics on 12 of the 12 factors compared between the two stocks.

About Global Industrial

Global Industrial Company operates as an industrial distributor of various industrial and maintenance, repair, and operation (MRO) products in North America. It offers storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, foodservice and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw materials. The company offers industrial and MRO products under the Global, GlobalIndustrial.com, Nexel, Paramount, Interion, and Absocold trademarks. It serves businesses; state, local, and private educational organizations; and government entities through relationship marketers, e-commerce sites, signature campaigns, and catalogs. The company was formerly known as Systemax Inc. Global Industrial Company was founded in 1949 and is headquartered in Port Washington, New York.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.